Latest news

LATEST NEWS

  • Bioactive Adrenomedullin, measured with sphingotec’s bio-ADM® assay plays a key role in septic shock patients as top-line results of AdrenOSS-2 Phase II Study indicate

    Bioactive Adrenomedullin, measured with sphingotec’s bio-ADM® assay plays a key role in septic shock patients as top-line results of AdrenOSS-2 Phase II Study indicate

  • Novel data on sphingotec’s biomarkers for acute and critical care settings  to be presented at AKI & CRRT 2020

    Novel data on sphingotec’s biomarkers for acute and critical care settings to be presented at AKI & CRRT 2020

  • sphingotec’s biomarker penKid® shows best representation of true glomerular filtration rate and has utility in patients with severe burns two studies show

    sphingotec’s biomarker penKid® shows best representation of true glomerular filtration rate and has utility in patients with severe burns two studies show

  • Hitado GmbH becomes Nexus IB10 distributor for sphingotec in Germany and Switzerland

    Hitado GmbH becomes Nexus IB10 distributor for sphingotec in Germany and Switzerland

  • sphingotec launches IVD test for kidney function biomarker penKid® on Nexus IB10 POCT platform

    sphingotec launches IVD test for kidney function biomarker penKid® on Nexus IB10 POCT platform

  • sphingotec transforms into end-to-end diagnostic solutions provider and exclusively represents Nexus Dx IB10 immunoassay portfolio

    sphingotec transforms into end-to-end diagnostic solutions provider and exclusively represents Nexus Dx IB10 immunoassay portfolio

  • sphingotec’s endothelial function biomarker bio-ADM® predicts need for organ support in general ICU patient population

    sphingotec’s endothelial function biomarker bio-ADM® predicts need for organ support in general ICU patient population

  • sphingotec’s biomarker penKid® predicts septic acute kidney injury at time of admission to emergency department

    sphingotec’s biomarker penKid® predicts septic acute kidney injury at time of admission to emergency department

  • sphingotec’s proprietary biomarker bio-ADM® detects residual congestion in patients with heart failure

    sphingotec’s proprietary biomarker bio-ADM® detects residual congestion in patients with heart failure

  • Sphingotec to Present Novel Acute Care Biomarkers and Point-of-Care Diagnostic Solutions at Medica 2019

    Sphingotec to Present Novel Acute Care Biomarkers and Point-of-Care Diagnostic Solutions at Medica 2019

  • Novel Data on sphingotec’s penKid® Kidney Function Assay to be Presented at 32nd ESICM Annual Congress 2019

    Novel Data on sphingotec’s penKid® Kidney Function Assay to be Presented at 32nd ESICM Annual Congress 2019

  • Dipeptidyl Peptidase 3 (DPP3) cause of acute myocardial depression. sphingotec launches first IVD test for DPP3 on Nexus IB10 Point-of-Care platform

    Dipeptidyl Peptidase 3 (DPP3) cause of acute myocardial depression. sphingotec launches first IVD test for DPP3 on Nexus IB10 Point-of-Care platform

  • sphingotec reveals novel results on bioactive adrenomedullin for diagnosis and therapy monitoring of septic shock at the 39th International Symposium on Intensive Care and Emergency Medicine (ISICEM)

    sphingotec reveals novel results on bioactive adrenomedullin for diagnosis and therapy monitoring of septic shock at the 39th International Symposium on Intensive Care and Emergency Medicine (ISICEM)

  • sphingotec announces new data on the kidney function marker proenkephalin (penKid®) presented at 24th International Conference on Advances in Critical Care Nephrology

    sphingotec announces new data on the kidney function marker proenkephalin (penKid®) presented at 24th International Conference on Advances in Critical Care Nephrology

  • Endothelial disruption: Rapid translation from bench to bedside 

    Endothelial disruption: Rapid translation from bench to bedside 

  • sphingotec raises €20 million from HBM and Wellington Partners

    sphingotec raises €20 million from HBM and Wellington Partners

  • sphingotec is adding an advanced POC testing platform to portfolio

    sphingotec is adding an advanced POC testing platform to portfolio

  • Medical leaders support novel theranostic approach to help patients with leaky blood vessels

    Medical leaders support novel theranostic approach to help patients with leaky blood vessels

  • Ortho Clinical Diagnostics and sphingotec Announce Strategic Agreement Regarding Novel Biomarker for Decreasing Re-hospitalizations in Heart Failure

    Ortho Clinical Diagnostics and sphingotec Announce Strategic Agreement Regarding Novel Biomarker for Decreasing Re-hospitalizations in Heart Failure

  • sphingotec Announces Collaboration with Mayo Clinic for Evaluation and Use of Biomarkers

    sphingotec Announces Collaboration with Mayo Clinic for Evaluation and Use of Biomarkers

  • Review paper on Proenkephalin as a Novel Biomarker for Kidney Function

    Review paper on Proenkephalin as a Novel Biomarker for Kidney Function

  • sphingotec and Shuwen Biotech partner to market sphingotec´s biomarkers portfolio in China

    sphingotec and Shuwen Biotech partner to market sphingotec´s biomarkers portfolio in China

  • sphingotec and bestbion dx partner to market predictive biomarkers for guidance of therapy in acute heart failure and septic shock

    sphingotec and bestbion dx partner to market predictive biomarkers for guidance of therapy in acute heart failure and septic shock

  • Good microcirculation indicates increased lifespan

    Good microcirculation indicates increased lifespan

  • Does the Hormone Neurotensin Hold the Key to a Longer Life?

    Does the Hormone Neurotensin Hold the Key to a Longer Life?

  • Survey: Majority of Women Do Not Discuss Breast Cancer Risks or Mammography Screening Limitations with Healthcare Providers

    Survey: Majority of Women Do Not Discuss Breast Cancer Risks or Mammography Screening Limitations with Healthcare Providers

  • Researchers Link Low Levels of Pro-Enkephalin to Future Breast Cancer in Healthy Women

    Researchers Link Low Levels of Pro-Enkephalin to Future Breast Cancer in Healthy Women

  • Majority of Women Do Not Discuss Breast Cancer Risks with Healthcare Providers

    Majority of Women Do Not Discuss Breast Cancer Risks with Healthcare Providers

  • sphingotec at the St. Gallen International Breast Cancer Conference

    sphingotec at the St. Gallen International Breast Cancer Conference

  • sphingotec and GeneNews Limited/Innovative Diagnostics Laboratory (IDL) Sign a Licensing and Cooperation Agreement for the U.S. Market

    sphingotec and GeneNews Limited/Innovative Diagnostics Laboratory (IDL) Sign a Licensing and Cooperation Agreement for the U.S. Market

Top